2.74

1.86% 0.05

Pre-market: 2.71 -0.03 -1.09%

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $2.74, with a volume of 1.20M. It is up +1.86% in the last 24 hours and down -3.18% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$2.69

Open:

$2.755

24h Volume:

1.20M

Relative Volume:

0.54

Market Cap:

$535.12M

Revenue:

$7.12M

Net Income/Loss:

$-24.17M

P/E Ratio:

-11.26

EPS:

-0.2434

Net Cash Flow:

$-41.95M

1W Performance:

-2.14%

1M Performance:

-3.18%

6M Performance:

+39.09%

1Y Performance:

+117.46%

1-Day Range:

$2.6901

$2.795

1-Week Range:

$2.61

$2.81

52-Week Range:

$1.12

$3.105

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (598)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2026-08-12

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	2.74	525.35M	7.12M	-24.17M	-41.95M	-0.2434
VRTX Vertex Pharmaceuticals Inc	519.51	130.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.74	80.46B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	990.54	61.58B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	146.69	57.48B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	205.11	43.68B	742.00K	-1.37B	-1.07B	-7.0731

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-25	Initiated	Roth Capital	Buy
Nov-17-25	Initiated	Leerink Partners	Outperform
Oct-09-25	Initiated	Oppenheimer	Outperform
Aug-08-25	Resumed	B. Riley Securities	Buy
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

Sep 12, 2026

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two - Yahoo! Finance Canada

Sep 12, 2026

Sep 11, 2026

OVID Maintained by HC Wainwright & Co. -- Price Target Raised to $5.00 - GuruFocus

Sep 11, 2026

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress - Investing.com

Sep 11, 2026

Sep 09, 2026

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus By Investing.com - Investing.com Canada

Sep 09, 2026

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus - Investing.com

Sep 09, 2026

Ovid Therapeutics Inc (NASDAQ: OVID) Share Price, OVID Stock News, OVID Share Price & Updates - Kalkine

Sep 09, 2026

Sep 05, 2026

Ovid Therapeutics Stock Price Forecast. Should You Buy OVID? - StockInvest.us

Sep 05, 2026

Sep 04, 2026

September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - RTTNews

Sep 04, 2026

Sep 03, 2026

Ovid management has two September talks scheduled - Stock Titan

Sep 03, 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 03, 2026

Aug 30, 2026

OVID Financials: Income Statement, Balance Sheet & Cash Flow | Ovid Therapeutics Inc - Stock Titan

Aug 30, 2026

Aug 24, 2026

Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan

Aug 24, 2026

Aug 22, 2026

Ovid (OVID) Shares: Posts a 2.19% Gain to $2.80; Range Check: the Supplied Trading Band Runs From $2.66 to $2.94 in the Latest ReadingDividend ETF - vinanet.vn

Aug 22, 2026

Aug 21, 2026

Ovid (OVID) Momentum: Finishes 2.19% Higher at $2.80 at the Close; Range View: Traders Can Monitor the $2.66-$2.94 Range in the Current UpdateDeath Cross - vinanet.vn

Aug 21, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus

Aug 20, 2026